# A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies

> **NCT00977067** · PHASE1 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Solid Cancers

## Interventions

- **DRUG:** GDC-0152

## Key facts

- **NCT ID:** NCT00977067
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** The study was terminated early by the Sponsor for reasons unrelated to patient safety or anti-tumor activity.
- **Last updated:** 2017-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977067, "A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00977067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*